Zepbound Eli Lilly Results

Order byBest matchMost fresh

Eli Lilly, Zepbound

Digest more

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

Zepbound achieved an average weight reduction of 20.2% compared to 13.7% with Wegovy after 72 weeks, it said.

· 2d · on MSN

PMLive · 3h

Eli Lilly’s Zepbound shows superiority in head-to-head weight loss study

· 2d · on MSN

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

· 2d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

Hosted on MSN2d

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine and presented at the European Congress on Obesity.

12don MSN

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell roughly 10% on investor worries that the move could blunt its sales momentum.

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.